Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A European Medicines Agency panel recommended approving a diabetes drug from Boehringer Ingelheim GmbH and Eli Lilly and Co. that was rejected this month in the United States because of manufacturing deficiencies.
The medicine, Jardiance, should be approved as a treatment for type 2 diabetes, the agency’s Committee for Medicinal Products for Human Use said in a prepared statement Friday. The European Commission usually follows the panel’s advice.
Indianapolis-based Lilly is expected to garner $518 million in annual sales from Jardiance by 2019, according to the average of five analyst estimates compiled by Bloomberg.
http://www.ibj.com/lilly-diabetes-drug-wins-backing-from-eu-regulator/PARAMS/article/46790
The medicine, Jardiance, should be approved as a treatment for type 2 diabetes, the agency’s Committee for Medicinal Products for Human Use said in a prepared statement Friday. The European Commission usually follows the panel’s advice.
Indianapolis-based Lilly is expected to garner $518 million in annual sales from Jardiance by 2019, according to the average of five analyst estimates compiled by Bloomberg.
http://www.ibj.com/lilly-diabetes-drug-wins-backing-from-eu-regulator/PARAMS/article/46790